We Accept amex

Formerly known as Maylips.com

info@directdoctorsupply.com+1-800-325-7104

Logo Logo
Track delivery Wishlist
  • 0 $ 0.00
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KARISMA
    • LEMONBOTTLE
    • LANLUMA
    • LIPORASE®
    • MEDIDERMA®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
Logo Logo
Menu
Close
Wishlist
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • BOTULAX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INNOTOX®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KAIMAX
    • KARISMA
    • LEMONBOTTLE
    • LETYBO®
    • LANLUMA
    • LIPORASE®
    • LIZTOX®
    • MEDIDERMA®
    • MEDITOXIN®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NABOTA® (JEUVEAU®)
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • Re N Tox™
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
  • 0 $ 0.00
Direct Doctor SupplyPeptides for ResearchWeight Loss & Metabolic PeptidesSemaglutide
Product Category
  • Anaesthetics (2)
  • Body Sculpting (4)
  • Botulinum Toxins (33)
  • Cannulas and Needles (13)
  • Cellular Rejuvenation (1)
  • Dermal Filler Removal (2)
  • Dermal Fillers (192)
  • Biostimulators (10)
  • HA Dermal Fillers (129)
  • Korean Dermal Fillers (28)
  • Polynucleotides (17)
  • Skinboosters (16)
  • Exosomes (1)
  • Eyelash Enhancers (1)
  • Fat Removal (3)
  • Gynecology (8)
  • IV Therapy (2)
  • Mesotherapy (23)
  • Orthopedic Injections (11)
  • Peels and Masks (23)
  • Peptides for Research (45)
  • Aesthetic & Cosmetic Peptides (1)
  • Brain, Cognitive & Nootropic Peptides (4)
  • Healing & Regenerative Peptides (6)
  • Immune & Thymic Peptides (4)
  • Longevity & Anti-Aging Peptides (7)
  • Muscle Growth & Performance Peptides (11)
  • Sexual Health & Hormonal Peptides (3)
  • Weight Loss & Metabolic Peptides (11)
  • PRP Kits (1)
  • Skincare (26)
  • Threads (28)
  • PCLA Threads (3)
  • PDO Threads (20)
  • PLA Threads (3)
  • Weight Loss (24)
Product Brand
  • ALIAXIN® (6)
  • ALIDYA™ (1)
  • AQUALYX® (1)
  • AZZALURE® (1)
  • BCN (12)
  • BELLAST® (3)
  • BELOTERO® (7)
  • BIOMEDICO (3)
  • BIOREPEELCL3® (2)
  • BOCOUTURE® (XEOMIN®) (3)
  • BOTOX® (6)
  • CAREGEN (2)
  • CINGAL® (1)
  • CRESPINE® (1)
  • CROMA (4)
  • CYTOCARE (4)
  • DEPO-PROVERA® (1)
  • DERMALAX™ (3)
  • DESIRIAL® (2)
  • DUROLANE® (1)
  • DYSPORT® (4)
  • EJAL (1)
  • ELLANSÉ™ (2)
  • EMLA™ (2)
  • EUFLEXXA® (1)
  • EXOJUV (1)
  • FILLMED® (14)
  • FILORGA® (2)
  • GARDASIL® (1)
  • HArmonyCA™ (1)
  • HYACORP (5)
  • HYAFILIA® (2)
  • HYALGAN® (1)
  • HYMOVIS® (1)
  • HYNIDASE® (1)
  • INTRALINE® (24)
  • JALUPRO® (5)
  • JAYDESS® (1)
  • JUVÉDERM® (13)
  • KARISMA (1)
  • LANLUMA (1)
  • LEMONBOTTLE (1)
  • LIPORASE® (1)
  • MEDIDERMA® (26)
  • MESO-RELLE® (2)
  • MESOESTETIC® (2)
  • MICRONJET™ (1)
  • MIRENA® (1)
  • MONOVISC® (1)
  • MOUNJARO® (9)
  • NEAUVIA™ (11)
  • NEURAMIS® (1)
  • NEXPLANON® (2)
  • NITHYA (3)
  • NOVERA COMPOUNDS (46)
  • NUCLEOFILL™ (8)
  • ORTHOVISC® (1)
  • OZEMPIC® (8)
  • PERFECTHA® (4)
  • PLASMOLIFTING™ (1)
  • PLINEST® (5)
  • PROFHILO® (3)
  • ​PROSTROLANE® (1)
  • PRX-T33® (1)
  • RADIESSE® (3)
  • RAINBOW (7)
  • REFINE (3)
  • REJURAN® (3)
  • REJUVANAD+ (2)
  • RENEFIL (3)
  • RESTYLANE® (10)
  • REVANESSE® (6)
  • REVOFIL (9)
  • REVOLAX™ (4)
  • SAXENDA® (1)
  • SAYPHA® (6)
  • SCULPTRA® (1)
  • SESDERMA® (10)
  • SILHOUETTE (3)
  • SMB® (1)
  • SOFTFIL® (6)
  • STYLAGE® (25)
  • SUNEKOS® (4)
  • SUPARTZ® (1)
  • SYNVISC® (2)
  • T-SAFE® (1)
  • TEOSYAL® (12)
  • ​THERASET® (1)
  • ULTRA V® (1)
  • VISCODERM® (2)
  • WEGOVY® (6)
  • XEOMEEN® (1)
  • XEOMIN® (4)
  • ZO® (3)

Semaglutide

Showing all 6 results

Sort By:
  • Cag+Sem 10mg FrontCag+Sem 10mg Back
    Cagrilintide 5mg + Semaglutide 5mg
    $ 119.00
    Read More
    -+
  • Semaglutide 10mg FrontSemaglutide 10mg Back
    Semaglutide 10mg
    $ 129.00
    Read More
    -+
  • Semaglutide 20mg FrontSemaglutide 20mg Back
    Semaglutide 20mg
    $ 159.00
    Read More
    -+
  • Coming Soon
    Semaglutide 2mg FrontSemaglutide 2mg Back
    Semaglutide 2mg
    $ 38.00
    Read More
  • Semaglutide 50mg FrontSemaglutide 50mg Back
    Semaglutide 50mg
    $ 279.00
    Read More
    -+
  • Semaglutide 5mg FrontSemaglutide 5mg Back
    Semaglutide 5mg
    $ 79.00
    Read More
    -+

Semaglutide is an FDA-approved GLP-1 receptor agonist and the reference compound in the modern weight loss and metabolic health landscape, available as Ozempic, Wegovy, Rybelsus, and compounded formulations for type 2 diabetes management, weight reduction, and cardiovascular risk reduction. Endocrinologists, obesity medicine specialists, metabolic disease clinicians, and compounding pharmacists will find a structured clinical overview of Semaglutide’s mechanisms, clinical evidence, dosing, safety profile, and comparisons with newer metabolic agents in the guide below. Practitioners seeking sourcing guidance or documentation support for Semaglutide may contact the Direct Doctor Supply support team.

How Does Semaglutide Work? GLP-1 Receptor Mechanism Explained

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and approved for weight management, treatment of type 2 diabetes, and cardiovascular risk reduction in specific patient populations [1], [2]. It acts exclusively through GLP-1 receptor activation, distinguishing it from dual-agonist therapies such as Tirzepatide and the investigational triple-agonist Retatrutide, which additionally engage GIP and glucagon receptors.

Semaglutide functions by binding GLP-1 receptors throughout the pancreas, gastrointestinal tract, and central nervous system, producing effects across several physiological pathways:

  • Pancreatic effects: Semaglutide enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby improving glycemic control in adults with type 2 diabetes while reducing the risk of hypoglycemia compared with insulin-independent secretagogues [2].
  • Appetite and satiety: Within the hypothalamus, Semaglutide activates satiety pathways that reduce appetite and caloric intake, the primary mechanism underlying its weight-management indication [1].
  • Gastric emptying: Semaglutide slows gastric motility, prolonging post-meal fullness and reducing postprandial glucose excursions, supporting its role as an adjunct to diet and exercise rather than a replacement for lifestyle interventions [1].
  • Cardiovascular effects: In the SUSTAIN-6 trial, Marso et al. (N Engl J Med, 2016) reported a significant reduction in major adverse cardiovascular events among patients with type 2 diabetes and established cardiovascular disease [2]. The SELECT trial subsequently demonstrated reduced cardiovascular risk in adults with established cardiovascular disease and overweight or obesity, without requiring a diagnosis of diabetes, further broadening the clinical significance of GLP-1 receptor agonism [3].

Semaglutide Forms: Ozempic, Wegovy, Rybelsus & Compound Semaglutide

Ozempic, Wegovy, and Rybelsus all contain semaglutide as their active ingredient but carry different FDA-approved indications and dosing protocols [3], [4]. They are distinct branded offerings from the same compound, not interchangeable formulations.

  • Ozempic is FDA-approved for glycemic control in adults with type 2 diabetes, reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduction of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [2], [3].
  • Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, and for reduction of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight [3]. It carries the highest approved dose of semaglutide currently available.
  • Rybelsus is an oral semaglutide option for adults with type 2 diabetes who prefer tablet administration to injections, available in doses of 3 mg, 7 mg, and 14 mg daily [5].
  • Compound semaglutide received significant attention during periods of branded product shortages. Compounded formulations differ from FDA-approved products and may involve different salt forms, manufacturing processes, and quality standards. The regulatory landscape governing compounding has evolved; practitioners should verify current rules before making procurement decisions.

Semaglutide for Weight Loss: Clinical Evidence & Outcomes

The strongest clinical evidence supporting semaglutide for weight loss comes from the STEP trial program. In STEP-1, Wilding et al. (N Engl J Med, 2021) demonstrated a mean body weight reduction of approximately 15% at 68 weeks among participants receiving semaglutide 2.4 mg weekly in addition to lifestyle intervention [1]. This outcome significantly exceeded results achieved through lifestyle modification alone and established semaglutide as one of the most effective FDA-approved obesity treatments at the time of publication.

All approved weight loss indications position semaglutide as an adjunct to diet and exercise. It is intended to support comprehensive metabolic management rather than replace behavioral interventions [1]. The weight-loss data originate from large Phase 3 randomized controlled trials, representing a high level of clinical evidence in obesity medicine.

Semaglutide Dosing: Injectable, Oral & Compound Forms

Appropriate dosing depends on the formulation, therapeutic objective, and patient tolerance. All dosing reflects FDA-approved labeling; practitioners should consult current prescribing information and apply individualized clinical judgment.

Injectable Semaglutide (Ozempic — T2DM)

Ozempic dosing is initiated at 0.25 mg once weekly for 4 weeks as a tolerability-introduction dose, not a therapeutic dose, before escalating to 0.5 mg once weekly. Further escalation proceeds based on clinical response and tolerability. Maximum doses and labeling have varied by country and across label revisions; practitioners should consult the current jurisdiction-specific prescribing information for up-to-date dosing limits.

Injectable Semaglutide (Wegovy — Weight Management and Cardiovascular Risk Reduction)

Wegovy follows a structured dose-titration schedule, beginning at 0.25 mg weekly and escalating in increments to a 2.4 mg weekly maintenance dose over approximately 16–20 weeks [4]. As of 2026, the FDA has approved an additional higher-dose 7.2 mg Wegovy injection option for some adults; practitioners should refer to the current Wegovy prescribing information for the full titration schedule and eligibility criteria for the higher-dose formulation [4]. Practitioners seeking to buy semaglutide wholesale for multi-patient clinic protocols should confirm that supplier documentation covers the specific formulation and dose being sourced.

Oral Semaglutide (Rybelsus — T2DM)

Oral semaglutide tablets are initiated at 3 mg daily for 30 days, followed by 7 mg daily for 30 days, with a maximum dose of 14 mg daily thereafter [5]. Patients must take Rybelsus on an empty stomach with no more than 4 ounces (approximately 120 mL) of plain water and wait at least 30 minutes before consuming food, drink, or other oral medications [5].

Compound Semaglutide Dosing

Dosing approaches for compounded semaglutide vary substantially across preparations and are not equivalent to those for the branded product. Healthcare professionals should recognize that compounded formulations are not FDA-approved equivalents and may differ in concentration, salt form, and handling requirements. All compound dosing should be treated as practitioner-directed rather than label-validated.

Is Semaglutide Safe? Side Effects & Safety Profile

The most commonly reported side effects are gastrointestinal in nature, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort [4]. These effects are dose-dependent and occur most frequently during dose escalation, typically improving after each titration step as tolerance develops.

Fatigue has been reported by some patients, particularly during the period when gastrointestinal side effects are most prominent. Clinical evidence indicates this is generally secondary to reduced food intake, dehydration, or GI symptoms rather than a direct pharmacological effect of GLP-1 receptor activation, and it typically resolves with dose stabilization [1].

Class-Level Risks

Clinicians should monitor for rare but clinically important risks, including acute pancreatitis, gallbladder disease, and cholelithiasis. Semaglutide labeling includes a boxed warning regarding thyroid C-cell tumors based on rodent study data; this association has not been confirmed in human clinical trials but remains an important prescribing consideration [4].

Compared with many newer metabolic agents, semaglutide offers one of the most established long-term safety datasets currently available, which is a meaningful differentiator for evidence-based prescribing and procurement decisions.

Legal Status of Semaglutide

Practitioners should independently verify the current regulatory status before making prescribing or procurement decisions, as guidance may evolve.

United States

Semaglutide is FDA-approved across three formulations with distinct indications [3], [4]:

  • Ozempic: glycemic control in adults with type 2 diabetes; reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduction of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
  • Wegovy: chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity; reduction of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight
  • Rybelsus: glycemic control in adults with type 2 diabetes

This represents one of the most comprehensive approval profiles in the metabolic peptide category.

Compound Semaglutide

The FDA previously permitted expanded compounding activity during branded product shortage periods. Shortage designations and the regulations governing the compounding of semaglutide have evolved and may continue to change. Practitioners should verify current compounding rules and applicable 503A/503B guidance before making procurement decisions.

WADA Status

Semaglutide does not currently appear on the World Anti-Doping Agency Prohibited List. Athletes and sports medicine practitioners should verify the current WADA list directly before any protocol consideration, as classifications are subject to annual revision.

Sourcing Semaglutide: Guidance for Licensed Practitioners

Semaglutide, in its injectable, oral, and compounded forms, is available only to qualified licensed medical professionals. Sourcing from verified suppliers with appropriate regulatory standing is essential to ensure product quality, purity, and documentation integrity.

When evaluating suppliers, practitioners should confirm:

  • A valid certificate of analysis (CoA) from an accredited third-party laboratory
  • LOT number traceability for each batch
  • Sterility and endotoxin testing documentation where applicable
  • Formulation-specific stability and handling documentation

Practitioners seeking to buy semaglutide online or to identify verified suppliers for compounded or research-grade formulations may contact Direct Doctor Supply for sourcing guidance and documentation. The support team can connect practitioners with suppliers meeting appropriate purity and traceability standards. For guidance on evaluating semaglutide sourcing options across formulations, contact the Direct Doctor Supply support team directly.

Semaglutide vs Tirzepatide & Retatrutide

Semaglutide vs Tirzepatide

The clinical comparison between semaglutide and Tirzepatide centers on receptor breadth and the magnitude of efficacy. Semaglutide acts exclusively through GLP-1 receptor agonism, whereas Tirzepatide combines GLP-1 and GIP receptor agonism; the additional GIP activity enhances insulin secretion and adipose tissue metabolism beyond what GLP-1 alone provides.

SURMOUNT-1 reported a mean body weight reduction of approximately 21% at the highest Tirzepatide dose, exceeding the approximately 15% reduction reported in STEP-1 for semaglutide [1]. Both are FDA-approved. Semaglutide may be preferred when clinicians prioritize long-term safety data, oral availability, and extensive prescribing experience; Tirzepatide may be favored when maximizing weight reduction is the primary objective.

Semaglutide vs Retatrutide

The comparison between semaglutide and Retatrutide reflects the evolution of metabolic peptide therapies toward increasing receptor complexity. Semaglutide remains the FDA-approved clinical standard, supported by extensive long-term data from the SUSTAIN, STEP, and SELECT programs [1], [2]. Retatrutide adds GIP and glucagon receptor activation to a GLP-1 foundation, creating a triple-agonist mechanism. Phase 2 results demonstrated weight reduction of up to approximately 24% at the highest dose studied. However, Retatrutide remains investigational, with Phase 3 TRIUMPH trials ongoing and no approved prescribing protocol in place.

Clinicians and procurement teams therefore face an approval-versus-efficacy horizon trade-off: semaglutide offers regulatory approval and mature safety data, while Retatrutide represents a potentially more potent but still investigational future option.

FAQs

What is Semaglutide, and is it the same as Ozempic?

Semaglutide is an FDA-approved GLP-1 receptor agonist available as Ozempic, Wegovy, and Rybelsus, all of which contain semaglutide as the active ingredient but carry different approved indications and dosing protocols [3], [4]. Ozempic is approved for glycemic control in T2DM, cardiovascular risk reduction in T2DM patients with established CVD, and kidney disease risk reduction in T2DM patients with CKD. Wegovy is approved for weight management and cardiovascular risk reduction in adults with established CVD and obesity or overweight. Compounded semaglutide formulations differ from these branded products and are not direct equivalents.

How does Semaglutide work?

Semaglutide activates GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, improving insulin secretion, suppressing glucagon release, reducing appetite, and slowing gastric emptying [1], [2]. Unlike Tirzepatide or Retatrutide, it has no GIP or glucagon receptor activity, making it a pure GLP-1 agonist.

What is the Semaglutide dosing for weight loss?

Wegovy dosing begins at 0.25 mg once weekly and escalates through a structured titration to a 2.4 mg weekly maintenance dose over approximately 16–20 weeks; as of 2026, a higher-dose 7.2 mg option is also available for some adults per the current prescribing label [4]. All dosing should follow FDA-approved labeling and individualized prescriber judgment; compound semaglutide protocols vary and are not FDA-validated equivalents.

What are the Semaglutide side effects, and how long do they last?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are most prominent during dose titration and typically improve within several weeks after each dose step [4]. Class-level risks include pancreatitis and gallbladder disease, which warrant appropriate clinical monitoring. Semaglutide labeling also includes a boxed warning regarding thyroid C-cell tumors from rodent data, not confirmed in human trials [4].

Does Semaglutide make you tired?

Fatigue has been reported during treatment initiation and dose escalation but is generally secondary to gastrointestinal symptoms and reduced food intake rather than a direct pharmacological effect [1]. It typically resolves with dose stabilization and is not a sustained pharmacological finding in STEP or SELECT trial data.

How does Semaglutide compare to Tirzepatide?

Semaglutide is a pure GLP-1 receptor agonist; Tirzepatide adds GIP receptor agonism, producing greater average weight loss in Phase 3 trials (approximately 21% vs. approximately 15%) [1]. Both are FDA-approved. Semaglutide offers a longer prescribing track record and an oral formulation; Tirzepatide may be preferred when maximizing weight reduction is the primary clinical goal.

Is Semaglutide legal, and what about compound Semaglutide?

Semaglutide is FDA-approved in the United States across three branded formulations, TGA-approved in Australia, and EMA-approved in the EU [3], [4]. Regulations governing compounded semaglutide have changed and may continue to evolve; practitioners should verify current compounding rules and applicable guidance before procurement.

References

  1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  2. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
  3. S. Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. Published March 8, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
  4. S. Food and Drug Administration. Wegovy (semaglutide) injection, for subcutaneous use: prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
  5. Novo Nordisk. How to Start RYBELSUS®. https://www.rybelsus.com/taking-rybelsus/how-to-start-rybelsus.html

All content on this website is intended for informational purposes and does not constitute medical advice.

Content prepared by Direct Doctor Supply’s editorial team.

Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.

SVG Logo Color cropped

info@directdoctorsupply.com

+1-800-325-7104

Book a MeetingTrack delivery
Trustpilot

Supported payment providers

Visa Mastercard American Express Google Pay Apple Pay

*Apple Pay and Google Pay are available via a personalized link provided by your account manager.

🔒 Transactions on this website meet strict PCI DSS compliance for your safety.

Product authenticity guaranteed: all products are sourced from licensed distributors and traceable by LOT number.

Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
  • Sitemap
Follow Us
  • Facebook
  • Instagram
  • LinkedIn
Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
Follow Us
  • Facebook
  • Instagram
  • Linkedin
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management

All peptide products sold by Direct Doctor Supply are Research Use Only (RUO) and intended solely for laboratory and scientific research. They are not FDA-approved and not for human or veterinary use, clinical, diagnostic, or therapeutic purposes. By purchasing RUO materials, you confirm they will be handled by qualified personnel in a proper research setting and in compliance with regulations. Products must not be administered to humans or animals or represented as safe or effective for medical use. Use is at your own risk; Direct Doctor Supply assumes no liability for misuse or regulatory issues.

2026 Direct Doctor Supply All rights reserved.
Terms Of Use Privacy Policy Refund and Replacement Shipping & Delivery